Author:
Möhler Markus,Götze Thorsten Oliver
Reference54 articles.
1. Ajani JA, Rodriguez W, Bodoky G et al.: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol Mar 20; 28 (9) (2010) 1547–1553. doi: 10.1200/JCO.2009.25.4706. Epub 2010 Feb 16. PMID: 20159816.
2. Al-Batran S-E, Goetze TO, Mueller DW et al.: The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17(1) (2017) 893. doi:10.1186/s12885-017-3918-9.
3. Al-Batran SE, Hartmann JT, Probst S et al.; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol Mar 20; 26 (9) (2008) 1435–1442. doi: 10.1200/JCO.2007.13.9378. PMID: 18349393.
4. Al-Batran S-E, Homann N, Pauligk C et al.: Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra. Lancet 393 (2019) 1948–1957.
5. Bang Y-J, Van Cutsem E, Feyereislova A et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (2010) 687–697.